Erythropoietin induces positive inotropic and lusitropic effects in murine and human myocardium

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 1, 2012, Pages 256-263

  Hefer, David ^a   Yi, Ting ^b   Selby, Donald E ^a   Fishbaugher, David E ^a   Tremble, Sarah M ^a   Begin, Kelly J ^a   Gogo, Prospero ^a   LeWinter, Martin M ^a,b   Meyer, Markus ^a   Palmer, Bradley M ^b   VanBuren, Peter ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Contractility; Erythropoietin; Heart failure; Myofilament; Protein kinase C

Indexed keywords

CHELERYTHRINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C EPSILON; RECOMBINANT ERYTHROPOIETIN; WORTMANNIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CELL FRACTIONATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HUMAN; HUMAN TISSUE; INOTROPISM; LUSITROPIC EFFECT; MOUSE; MUSCLE TWITCH; NONHUMAN; OSCILLATION; PHOSPHORYLATION; PRIORITY JOURNAL; SARCOMERE;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ERYTHROPOIETIN; HEART; HUMANS; MICE; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PAPILLARY MUSCLES; PROTEIN KINASE C; RECEPTORS, ERYTHROPOIETIN; SIGNAL TRANSDUCTION;

MURINAE;

EID: 84155194917     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.10.005     Document Type: Article

References (31)

1. Gao E., Boucher M., Chuprun J.K., Zhou R.H., Eckhart A.D., Koch W.J. Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 2007, 293:H60-H68.
2. Lin X., Fujita M., Kanemitsu N., Kimura Y., Tambara K., Premaratne G.U., et al. Sustained-release erythropoietin ameliorates cardiac function in infarcted rat-heart without inducing polycythemia. Circ J 2007, 71:132-137.
3. Cai Z., Semenza G.L. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004, 109:2050-2053.
4. Silverberg D.S., Wexler D., Sheps D., Blum M., Keren G., Baruch R., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37:1775-1780.
5. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242.
6. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004, 101:14907-14912.
7. Mulieri L.A., Hasenfuss G., Ittleman F., Blanchard E.M., Alpert N.R. Protection of human left ventricular myocardium from cutting injury with 2,3-butanedione monoxime. Circ Res 1989, 65:1441-1449.
8. Palmer B.M., Lynch J.M., Snyder S.M., Moore R.L. Renal hypertension prevents run training modification of cardiomyocyte diastolic Ca2+ regulation in male rats. J Appl Physiol 2001, 90:2063-2069.
9. Brines M., Patel N.S., Villa P., Brines C., Mennini T., De P.M., et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 2008, 105:10925-10930.
10. Palmer B.M., Chen Z., Lachapelle R.R., Hendley E.D., LeWinter M.M. Cardiomyocyte function associated with hyperactivity and/or hypertension in genetic models of LV hypertrophy. Am J Physiol Heart Circ Physiol 2006, 290:H463-H473.
11. Palmer B.M., Fishbaugher D.E., Schmitt J.P., Wang Y., Alpert N.R., Seidman C.E., et al. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium. Am J Physiol Heart Circ Physiol 2004, 287:H91-H99.
12. Hanlon P.R., Fu P., Wright G.L., Steenbergen C., Arcasoy M.O., Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 2005, 19:1323-1325.
13. Noguchi T., Hunlich M., Camp P.C., Begin K.J., El Zaru M., Patten R., et al. Thin filament-based modulation of contractile performance in human heart failure. Circulation 2004, 110:982-987.
14. Martiny-Baron G., Kazanietz M.G., Mischak H., Blumberg P.M., Kochs G., Hug H., et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 1993, 268:9194-9197.
15. Li D., Yang C., Chen Y., Tian J., Liu L., Dai Q., et al. Identification of a PKCepsilon-dependent regulation of myocardial contraction by epicatechin-3-gallate. Am J Physiol Heart Circ Physiol 2008, 294:H345-H353.
16. Jacobshagen C., Kortlepel S., Unsoeld B.W., Sowa T., Koegler H., Hasenfuss G., et al. Inhibition of PI3K improves contractility in alpha1-adrenergically stimulated myocardium. Front Biosci 2008, 13:6841-6849.
17. Takeishi Y., Chu G., Kirkpatrick D.M., Li Z., Wakasaki H., Kranias E.G., et al. In vivo phosphorylation of cardiac troponin I by protein kinase Cbeta2 decreases cardiomyocyte calcium responsiveness and contractility in transgenic mouse hearts. J Clin Invest 1998, 102:72-78.
18. Braz J.C., Gregory K., Pathak A., Zhao W., Sahin B., Klevitsky R., et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004, 10:248-254.
19. Piuhola J., Kerkela R., Keenan J.I., Hampton M.B., Richards A.M., Pemberton C.J. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Clin Sci (Lond) 2008, 114:293-304.
20. Kaygisiz Z., Erkasap N., Yazihan N., Sayar K., Ataoglu H., Uyar R., et al. Erythropoietin changes contractility, cAMP, and nitrite levels of isolated rat hearts. J Physiol Sci 2006, 56:247-251.
21. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003, 112:999-1007.
22. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002, 8:495-505.
23. Lipsic E., van der M.P., Voors A.A., Westenbrink B.D., van den Heuvel A.F., de Boer H.C., et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006, 20:135-141.
24. Maiese K., Li F., Chong Z.Z. New avenues of exploration for erythropoietin. JAMA 2005, 293:90-95.
25. Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004, 113:1535-1549.
26. Shi Y., Rafiee P., Su J., Pritchard K.A., Tweddell J.S., Baker J.E. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 2004, 99:173-182.
27. Schreiber K.L., Paquet L., Allen B.G., Rindt H. Protein kinase C isoform expression and activity in the mouse heart. Am J Physiol Heart Circ Physiol 2001, 281:H2062-H2071.
28. Kang M., Walker J.W. Protein kinase C delta and epsilon mediate positive inotropy in adult ventricular myocytes. J Mol Cell Cardiol 2005, 38:753-764.
29. Johnson J.A., Gray M.O., Chen C.H., Mochly-Rosen D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J Biol Chem 1996, 271:24962-24966.
30. Gray M.O., Karliner J.S., Mochly-Rosen D. A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem 1997, 272:30945-30951.
31. Coleman T.R., Westenfelder C., Togel F.E., Yang Y., Hu Z., Swenson L., et al. Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci U S A 2006, 103:5965-5970.